Cargando…

Factors influencing the outcome of vedolizumab treatment: Real‐life data with objective outcome measurements

BACKGROUND: Vedolizumab (VDZ), a humanised monoclonal antibody against a4ß7‐integrin, has shown efficacy in inflammatory bowel disease (IBD). It is of importance to assess the mid‐to long‐term efficacy of VDZ using real‐life data. OBJECTIVE: Our study aimed to determine the efficacy of VDZ in patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mader, Orla, Juillerat, Pascal, Biedermann, Luc, Michetti, Pierre, Hruz, Petr, Pittet, Valerie, Rogler, Gerhard, Zahnd‐Straumann, Nadine, Seibold, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259282/ https://www.ncbi.nlm.nih.gov/pubmed/33203339 http://dx.doi.org/10.1177/2050640620965106

Ejemplares similares

Outcome of tacrolimus and vedolizumab after corticosteroid and anti-TNF failure in paediatric severe colitis
por: Hamel, Blaise, et al.
Publicado: (2018)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis
por: Bethge, Johannes, et al.
Publicado: (2017)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD
por: Soendergaard, Christoffer, et al.
Publicado: (2018)

Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6‐week open‐label trial of the EOS‐2 Programme
por: Miehlke, Stephan, et al.
Publicado: (2022)

The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients
por: Roth, René, et al.
Publicado: (2021)

Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
por: Yokomizo, Lauren, et al.
Publicado: (2016)

Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial
por: Feagan, B. G., et al.
Publicado: (2016)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome
por: Ruiz, Pedro A, et al.
Publicado: (2017)

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)
por: Danese, Silvio, et al.
Publicado: (2019)

Factors affecting outcomes in Crohn's disease over 15 years
por: Cosnes, Jacques, et al.
Publicado: (2012)

Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Developing a core outcome set for fistulising perianal Crohn’s disease
por: Sahnan, Kapil, et al.
Publicado: (2019)

Outcomes of inflammatory bowel disease in patients with eosinophil-predominant colonic inflammation
por: Alhmoud, Tarik, et al.
Publicado: (2020)

Transmural remission improves clinical outcomes up to 5 years in Crohn's disease
por: Fernandes, Samuel Raimundo, et al.
Publicado: (2022)

Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta‐analysis
por: Magro, Fernando, et al.
Publicado: (2021)

Genital warts and inflammatory bowel diseases: Danish real‐world evidence to assess patient‐relevant outcomes
por: McLellan, Paul, et al.
Publicado: (2022)

Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life
por: Kanis, Shannon Linda, et al.
Publicado: (2021)

Ulcerative colitis: Impact of early disease clearance on long‐term outcomes ‐ A multicenter cohort study
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience
por: Hoque, Sami, et al.
Publicado: (2020)

Long‐term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study
por: Festa, Stefano, et al.
Publicado: (2021)

Worse outcomes and higher costs of care in fibrostenotic Crohn’s disease: a real-world propensity-matched analysis in the USA
por: Dehghan, Melody, et al.
Publicado: (2021)

PICaSSO virtual electronic chromendoscopy accurately reflects combined endoscopic and histological assessment for prediction of clinical outcomes in ulcerative colitis
por: Nardone, Olga Maria, et al.
Publicado: (2022)

Fecal lactoferrin early predicts long‐term outcomes in ulcerative colitis: A post‐hoc analysis of the UNIFI and PURSUIT trials
por: Chen, Rirong, et al.
Publicado: (2023)

Cytomegalovirus colitis in inflammatory bowel disease and after haematopoietic stem cell transplantation: diagnostic accuracy, predictors, risk factors and disease outcome
por: Mavropoulou, Eirini, et al.
Publicado: (2019)

Impact of the coronavirus infectious disease (COVID-19) pandemic on the provision of inflammatory bowel disease (IBD) antenatal care and outcomes of pregnancies in women with IBD
por: Selinger, Christian Philipp, et al.
Publicado: (2021)

Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource
por: Stournaras, Evangelos, et al.
Publicado: (2021)

Development and initial psychometric validation of a patient-reported outcome measure for Crohn’s perianal fistula: the Crohn’s Anal Fistula Quality of Life (CAF-QoL) scale
por: Adegbola, Samuel O, et al.
Publicado: (2021)

Ferric maltol Real-world Effectiveness Study in Hospital practice (FRESH): clinical characteristics and outcomes of patients with inflammatory bowel disease receiving ferric maltol for iron-deficiency anaemia in the UK
por: Cummings, JR Fraser, et al.
Publicado: (2021)

Mitochondrial impairment drives intestinal stem cell transition into dysfunctional Paneth cells predicting Crohn’s disease recurrence
por: Khaloian, Sevana, et al.
Publicado: (2020)

Use of complementary and alternative medicine and low quality of life associate with the need for psychological and psychotherapeutic interventions in inflammatory bowel disease
por: Kutschera, Maximilian, et al.
Publicado: (2021)

First Multicenter Study of Modified Release Phosphatidylcholine “LT-02” in Ulcerative Colitis: A Randomized, Placebo-Controlled Trial in Mesalazine-Refractory Courses
por: Karner, Max, et al.
Publicado: (2014)

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

A microbial signature for Crohn's disease
por: Pascal, Victoria, et al.
Publicado: (2017)

Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases
por: Michaudel, Chloé, et al.
Publicado: (2023)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse
por: Arrieta, M C, et al.
Publicado: (2008)

Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition
por: Binion, D G, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_63okmk4m1fj19qg4trktl03lod